Biogenera
The unique and patented biotechnology platform to generate personalized DNA drugs for incurable diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 -173.3x EV/EBITDA | round | |
* | €1.6m Valuation: €80.3m 135.4x EV/Revenue | Seed | |
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | - | 49 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | - | (151 %) | (127 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Biogenera operates in the biopharmaceutical sector, focusing on the research, development, and commercialization of innovative therapies for rare genetic diseases. The company serves patients, healthcare providers, and pharmaceutical partners by developing precision medicines that address unmet medical needs. Biogenera's business model revolves around leveraging advanced genetic research to create proprietary drugs, which are then brought to market through collaborations with larger pharmaceutical companies or direct commercialization. Revenue is generated through licensing agreements, partnerships, and direct sales of their therapeutic products. The company also engages in strategic alliances with universities, research centers, and certified incubators to enhance its research capabilities and accelerate drug development.
Keywords: biopharmaceuticals, genetic diseases, precision therapies, drug development, licensing, partnerships, healthcare, innovation, research, commercialization.